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Abstract
© 2017 by the authors. The fact that most gastrointestinal stromal tumors (GISTs) acquire
resistance to imatinib (IM)-based targeted therapy remains the main driving force to identify
novel molecular targets that are capable to increase GISTs sensitivity to the current therapeutic
regimens. Secondary resistance to IM in GISTs typically occurs due to several mechanisms that
include hemi-  or  homo-zygous deletion of  the wild-type KIT  allele,  overexpression of  focal
adhesion kinase (FAK) and insulin-like growth factor receptor I  (IGF-1R) amplification, BRAF
mutation,  a  RTK  switch  (loss  of  c-KIT  and  gain  of  c-MET/AXL),  etc.  We  established  and
characterized the IM-resistant GIST T-1 cell line (GIST T-1R) lacking secondary c-KIT mutations
typical for the IM-resistant phenotype. The resistance to IM in GIST T-1R cells was due to RTK
switch (loss of c-KIT/gain of FGFR2α).  Indeed, we have found that FGFR inhibition reduced
cellular viability, induced apoptosis and affected the growth kinetics of the IM-resistant GISTs in
vitro.  In contrast,  IM-naive GIST T-1 parental  cells were not susceptible to FGFR inhibition.
Importantly, inhibition of FGF-signaling restored the susceptibility to IM in IM-resistant GISTs.
Additionally, IM-resistant GISTs were less susceptible to certain chemotherapeutic agents as
compared to parental IM-sensitive GIST cells. The chemoresistance in GIST T-1R cells is not due
to overexpression of ABC-related transporter proteins and might be the result of upregulation of
DNA damage signaling and repair (DDR) genes involved in DNA double-strand break (DSB)
repair pathways (e.g.,  XRCC3, Rad51, etc.).  Taken together, the established GIST T-1R cell
subline might be used for in vitro and in vivo studies to examine the efficacy and prospective
use of FGFR inhibitors for patients with IM-resistant, un-resectable and metastatic forms of
GISTs with the type of RTK switch indicated above.
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